Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Australian Clinical Labs Ltd ( (AU:ACL) ) has provided an announcement.
Australian Clinical Labs Limited has released its financial results for the fiscal year 2025. The announcement includes the FY25 financial statements, statutory reports, and an investor presentation. This release is significant for stakeholders as it provides insights into the company’s financial health and operational performance, potentially impacting its market positioning and future strategic decisions.
The most recent analyst rating on (AU:ACL) stock is a Buy with a A$3.00 price target. To see the full list of analyst forecasts on Australian Clinical Labs Ltd stock, see the AU:ACL Stock Forecast page.
More about Australian Clinical Labs Ltd
Australian Clinical Labs (ACL) is a leading private provider of pathology services in Australia. The company operates NATA accredited laboratories that conduct a wide range of pathology tests for doctors, specialists, patients, hospitals, and corporate clients. ACL is recognized as one of the largest private hospital pathology businesses in the country, focusing on combining skilled personnel, medical and scientific leadership, and innovative technologies to enhance decision-making that saves and improves patients’ lives.
Average Trading Volume: 913,236
Technical Sentiment Signal: Sell
Current Market Cap: A$492.9M
For detailed information about ACL stock, go to TipRanks’ Stock Analysis page.